Drug developer Indevus Pharmaceuticals Inc. said Friday an independent group of experts recommended the company discontinue the high dosage of its experimental product to prevent HIV.
The product, PRO 2000, is a topical vaginal product under development to prevent the sexual transmission of HIV and other sexually transmitted diseases.
The United Kingdom's Medical Research Council, a human health organization, advised Indevus to close the high-dose group after reviewing data from a Phase III clinical trial of PRO 2000.
An independent data-monitoring committee said the high-dose group in the trial showed only a small chance that the high dose will protect against HIV infection compared with a placebo gel.
The committee, however, recommended the low dosage in the trial continue to be tested for safety and effectiveness.
Shares of Indevus fell 3 cents to $6.10.
No comments:
Post a Comment